Indian Journal of Dermatology
  Publication of IADVL, WB
  Official organ of AADV
Indexed with Science Citation Index (E) , Web of Science and PubMed
 
Users online: 9238  
Home About  Editorial Board  Current Issue Archives Online Early Coming Soon Guidelines Subscriptions  e-Alerts    Login  
    Small font sizeDefault font sizeIncrease font size Print this page Email this page


 
Table of Contents 
BASIC RESEARCH
Year : 2020  |  Volume : 65  |  Issue : 3  |  Page : 173-177
Is NAT2 gene polymorphism associated with vitiligo?


1 Department of BTMM and Biochemistry, PGIMS, Pt. B.D. Sharma University of Health Sciences, Rohtak, Haryana, India
2 Department of Skin and VD, PGIMS, Pt. B.D. Sharma University of Health Sciences, Rohtak, Haryana, India
3 College of Pharmacy, PGIMS, Pt. B.D. Sharma University of Health Sciences, Rohtak, Haryana, India

Date of Web Publication14-Apr-2020

Correspondence Address:
Daya Shankar Lal Srivastava
Department of BTMM and Biochemistry, Pt. B.D. Sharma Post Graduate Institute of Medical Sciences, Rohtak - 124 001, Haryana
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijd.IJD_388_18

Rights and Permissions

   Abstract 


Background: N-acetyltransferase-2 (NAT2) is a phase II xenobiotic enzyme that plays an important role against oxidative stress-mediated reactive oxygen species protection. Polymorphism in specific genotypes of NAT2 may lead to increase an imbalance in antioxidant systems and may influence the pathogenesis of vitiligo. We conducted this study to see the association between NAT2 gene polymorphism and risk of vitiligo. We looked into whether single-nucleotide polymorphisms (SNP) at positions 857, 481 and 590 of the coding region of the NAT2 gene play as a risk factor for vitiligo among north Indian people. Materials and Methods: In this study, we assessed 100 patients with vitiligo and 160 healthy individuals as controls. Genomic DNA was extracted from human peripheral blood and polymerase chain reaction–restricted fragment length polymorphism was done to identify the single nucleotide polymorphism at positions 857, 481, and 590 of the coding region of the NAT2 gene. Results: In this study, we observed a significant higher risk with slow acetylator genotypes of NAT2 (OR = 2.85; 95% CI = 1.68-4.84, P value < 0.001) for the vitiligo. Furthermore, in the association between NAT2 acetylator genotypes with percentage of body surface area (BSA) of disease, we observed that slow acetylator genotypes of NAT2 has significant higher risk with low grade of disease (1%–10% >11%–30% >30% of BSA). Limitations: A major limitation of this study was the small sample size and warrants further investigation on a large epidemiological study to confirm these findings. Conclusions: Our preliminary data indicate that NAT2 slow acetylator genotype exhibits significant association for the risk of vitiligo, especially in disease predisposition and initiation.


Keywords: Acetylator genotype, n-acetytransferase-2 gene, oxidative stress, vitiligo


How to cite this article:
Lal Srivastava DS, Aggarwal K, Singh G. Is NAT2 gene polymorphism associated with vitiligo?. Indian J Dermatol 2020;65:173-7

How to cite this URL:
Lal Srivastava DS, Aggarwal K, Singh G. Is NAT2 gene polymorphism associated with vitiligo?. Indian J Dermatol [serial online] 2020 [cited 2020 Aug 9];65:173-7. Available from: http://www.e-ijd.org/text.asp?2020/65/3/173/282455





   Introduction Top


Vitiligo is a multifactorial polygenic disorder of the skin characterized by depigmented patches due to loss of the melanocytes. It is caused by the complex interaction between genotypic and phenotypic environment of an individual. Worldwide, its incidence ranges from 0.1% to 3% in general population.[1],[2] However, in Indian subcontinent, India has the highest prevalence, varying from 0.25% to 2.5%.[3] There is no sex predilection for vitiligo, as such both sexes are affected equally.[1],[4] Exact pathogenesis of vitiligo is still unclear, however, more persuasive evidences are genetic, environmental, oxidative stress, biochemical, and immunological factors that seem to act together or individually to generate a lenient environment for the melanocyte loss.[5],[6],[7],[8],[9],[10],[11]

Recent studies show that besides the immunological and pathogenic mechanisms, oxidative stress may be an important contributor to the pathogenesis of melanocyte death.[5],[7] The imbalance between oxidative stress and antioxidation seems to induce excess production of reactive oxygen species (ROS) in the epidermal layer of skin, which may be an important pathogenic factor of vitiligo.[5],[7],[9],[11] Xenobiotic phase I (cytochrome P450s) and phase II enzymes (i.e. glutathione S-transferases [GSTs], N-acetyltransferases [NAT1 and NAT2]) play a major role in the biotransformation and protection against environmentally exposed exogenous and endogenous toxicants, i.e. drugs, carcinogens, hair dyes and several others.[10],[11],[12],[13],[14]N-acetyltransferase metabolizes wide range of xenobiotic compounds that may be responsible for ROS production and melanocyte damage via the acetylation process.[10],[11] It catalyzes the metabolic inactivation or activation of environmentally exposed compounds, such as plethora of hydrazine and arylamines by the pathways of n- or o-acetylation.[10],[11],[12],[13],[14]

NAT2 polymorphically expresses at a number of tissues such as liver and epidermis.[15] Humans express two forms of N-acetyltransferases: NAT1 and NAT2, both genes are polymorphic. Now, 24 alleles in NAT1 and >59 alleles in NAT2 have been identified.[16] A recent review described the nucleotide and amino acid changes associated with various alleles and deduced phenotype from NAT2 genotypes was generated.[17],[18] The NAT2 slow and fast acetylator phenotypes can be generated by existing SNPs in the coding region of the NAT2 gene, which influences the affinity for the substrate and catalytic activity of the protein. Consequently, the presence of the different alleles in each individual genome produces a broad range of metabolic phenotypes from fully active fast acetylator phenotype to the less active slow acetylator phenotype and it may vary in different populations due to different ethnic groups.[11],[17],[18],[19]

Out of several NAT2 alleles, three mutant alleles (NAT2*5, NAT2*6, and NAT2*7), which can be identified by the detection of the mutations at positions 481, 590, and 857 of the coding region of the NAT2 gene, have been shown to be associated with slow acetylator genotypes. Recent studies have shown that variation in NAT2 gene may modify the risk of various diseases, such as cancer,[17] psoriasis,[20] systematic lupus erythematosus,[21] contact allergy,[22] Alzheimer's, Parkinson's, diabetes mellitus, rheumatoid arthritis, and autoimmune diseases.[19] Search until August 22, 2018, in electronic databases, such as Medline (1966–Present), EMBASE (1980–Present), or in Google engine by typing of key words, i.e. NAT2 gene polymorphism and risk of vitiligo or genetic polymorphism of NAT2 gene for susceptibility of vitiligo disease, does not reveal any report on NAT2 with vitiligo risk was available in electronic database.

Published data suggest that the frequencies of NAT2 polymorphisms differ among different racial and ethnic groups.[17],[19],[22] Whether NAT2 genetic variants (i.e. NAT2*5, NAT2*7, and NAT2*6 alleles) can help to explain part of the large differences in vitiligo awaits further clarification. Therefore, this study was undertaken to study the following objectives: i) to observe the frequencies of rapid and slow acetylators (NAT2) in vitiligo and control individuals and ii) to study effect of NAT2 acetylators genotype on modifying the vitiligo risk on disease initiation.


   Materials and Methods Top


Sample size for the study was calculated by using the Epi Info 7 software. Approval for the study was obtained from the institutional review board. This study was conducted to see the association between NAT2 gene polymorphism and risk of vitiligo in 100 patients and 160 age- and sex-matched healthy controls. The ethnic origin of the cases and controls were similar. Patients with vitiligo vulgaris were selected in the study. Patients were selected on the basis of a questionnaire administered in the OPD of the institute that included medical records. Case records had been kept for each patient. Data had been systematically recorded as outlined in the proforma, such as gender, family history of disease, age at vitiligo onset, type and severity of the disease (percentage of body surface area [BSA] affected), and history of smoking. BSA was evaluated by the “rule of nines” method. Age- and sex-matched healthy individuals had been selected as control group for the study.

Inclusion criteria of the patient group were - 1) age between 18 and 75; 2) patients who never had previous vitiligo treatment, and 3) patients who had stopped taking systemic or topical medication 1 month prior to this study. However, those patients who have been smokers, those with chronic illness, pregnant ladies, or lactating mothers and had other autoimmune diseases, such as thyroid disorder, rheumatoid arthritis, and bronchial asthma were excluded from the study.

DNA extraction and NAT2 genotyping

For DNA extraction and genotyping, 5 mL of venous blood was collected in an EDTA vial from patients of study group and control group. Genomic DNA was extracted from blood lymphocytes using the proteinase K and phenol chloroform extraction procedure.[23]

The NAT2 genotypes were determined using the polymerase chain reaction (PCR)-RFLP as described previously.[24] PCR product of 1,092 bp was generated by PCR using the following primer: Forward 5′-TCTAGCATGAATCACTCTGC-3′, Reverse 5′- GGAACAAATTGGAC TTGG -3′ in a total volume of 50 μl. PCR was carried out in PTC-thermocycler (MJ Research) for 35 cycles. Following PCR, 7 μl of PCR products was digested with four separate enzymes including Kpn1 (5U; Fermentas) for NAT2*5 allele, at 37°C for 2 h; Taq1 (5U; Fermentas) for NAT2*6 allele, at 56°C for 4 h; and BamH1 (5U; Fermentas) for NAT2*7 allele at 37°C for 2 h. Digested product was run on 2% agarose gel for NAT2*5 and NAT2*7 alleles and 3% agarose gel for NAT2*6 allele [Table 1].
Table 1: Genetic polymorphism site of NAT2 and its different alleles

Click here to view


Estimating the frequency of rapid and slow acetylator

The variant and nonvariant alleles were recorded and phenotyping of NAT2 gene in vitiligo and control was done on the basis of NAT2 genotypes. For each group (case and control), frequency of rapid and slow acetylator genotypes were determined. The presence of two mutant alleles was defined as slow acetylator genotype, whereas one or zero mutant allele was segregated as rapid acetylator genotype.[25]

Statistical analysis

Statistical analysis was done with SPSS 20.0 software program. Differences in genotype prevalence and association between vitiligo disease and normal healthy groups were assessed by binary logistic regression model. Pvalue < 0.05 was considered significant for the study. Odds ratios (OR) and its 95% confidence interval (CI) were obtained by summarizing data over three strata for BSA (<10%, 11%–30%, and >30%). We evaluated age-adjusted (confounder OR) and unadjusted ORs and 95% CI by using logistic regression model. Univariant analysis, ORs, and 95% CI were used to describe the strength of association.


   Results Top


The present study included 100 vitiligo patients with a mean age of 30.9 years (± 16.98) and 160 normal healthy individuals as control having a mean age of 28.9 years (± 16.75). The distribution of NAT2 acetylator genotypes in control and vitiligo patients is shown in [Table 2]. Higher frequency of NAT2 slow acetylator was observed (70.0%) among the patient group as compared with the control (45.0%). It was statistically significant for susceptibility of vitiligo in north Indians (OR = 2.85; 95% CI = 1.68–4.84; P< 0.001).
Table 2: Association between NAT2 genotypes and body surface area of disease

Click here to view


We categorized severity of disease (BSA) into three groups (1%–10%, 11%–30%, and >30% of BSA). We observed that NAT2 slow acetylator genotypes were highly significant in low grade of disease (1%–10% >11%–30% >30% of BSA) when compared with controls for the susceptibility of vitiligo in our population as shown in [Table 3].
Tables 3: Association between NAT2 genotypes and percentage of body surface area of vitiligo disease

Click here to view


The association between NAT2 acetylator genotypes and gender has been summarized in [Table 4]. The OR for the slow acetylator genotypes was 2.99-fold higher for male and 2.79-fold higher for female as compared with the controls. It was statistically significant in both groups: male (P = 0.004) and female (P = 0.027).
Tables 4: Association between gender and NAT2 genotypes

Click here to view



   Discussion Top


Vitiligo is a multifactorial disorder and its pathophysiology is complex. Most environmental toxicants require metabolic activation to interact with DNA and exert their genotoxic potential that is probably associated with vitiligo risk. This activation is mediated by the action of phase I enzymes, such as cytochrome P4501A1. Furthermore, genotoxic chemicals, including reactive intermediates produced from the above enzymatic reactions undergo biotransformation by phase II (GSTs and NATs) enzymatic defensive mechanisms, into more polar and less toxic metabolites that can be easily excreted from the body.[6],[7],[10],[12],[14],[17]

NAT2 enzyme plays a very important role in xenobiotic biotransformation and protection against the environmental toxicants (i.e. drugs, carcinogens, hair dyes, and several other toxic irritants), which may be responsible for ROS production and melanocytes loss.[10],[11],[12],[13],[14] It catalyzes plethora of hydrazine and arylamines (i.e. paraphenylenediamine) metabolism by the two pathways: n-acetylation (inactivation)/o-acetylation (activation).[14],[17],[22],[26] The NAT2 gene is highly polymorphic and each mutant allele contains a combination of one or more nucleotide substitutions. Out of several NAT2 alleles, three mutant alleles (NAT2*5, NAT2*6, and NAT2*7) have been shown to be associated with slow acetylator genotypes. Previously published literature has shown that NAT2 slow acetylator genotypes have been linked with increased susceptibility of various diseases,[10],[11],[12],[13],[14],[22],[26] but there is no report from vitiligo.

In present case–control study, higher frequency of NAT2 slow acetylator was observed (70.0%) among the patient group when compared with the controls (45.0%) (P < 0.001). Our study demonstrated 2.85-fold higher risk for predisposition of vitiligo (OR = 2.85; P < 0.001) [Table 2] in those persons who possess slow acetylator genotypes of NAT2. Furthermore, in association between BSA and NAT2 slow acetylator genotypes, we observed significant higher risk in low grade of disease (BSA = 1%–10%; P = 0.007) and its trend in BSA categories was in the order of 1%–10% >11%–30% >30% for predisposition of vitiligo [Table 3]. Our findings are in agreement with previous studies reported in various diseases that showed significant association with slow acetylator genotypes of NAT2 for susceptibility of contact allergic,[22] atopic dermatitis,[27] systemic sclerosis and lupus erythematosus,[21],[28] Alzheimer's, Parkinson's, diabetes mellitus, rheumatoid arthritis and autoimmune disorders,[19] sulphonamide-induced toxic epidermal necrolysis and Stevens–Johnson syndrome,[29] as well as psoriasis and other diseases.[20] However, studies from north India[24] and Turky[30] have shown an increased risk of prostate cancer and allergic contact dermatitis with fast acetylator genotypes of NAT2. The discrimination in association study observed in various populations could be related to ethnic variation. Finding of our study could be suggested that nonacetylated xenobiotics may accumulate in slow acetylator persons and are subsequently metabolized by other enzymes (i.e. CYPs) into reactive intermediates.[5],[6],[7],[10],[12],[14],[22] These reactive intermediates may alter self-proteins and affected NAT2 enzyme specificity and activity, which, in turn, initiate pathological and clinical signs of vitiligo. We have detected significant association with slow acetylator genotypes of NAT2 to the risk of vitiligo in the north Indian population, suggesting that the NAT2 slow acetylator genotypes may be an important risk factor in the pathogenesis of disease especially for initiation/predisposition of vitiligo.

Furthermore, correlation of NAT2 genotypes with gender, we observed significant association with slow acetylator genotypes of NAT2 in both sexes for the susceptibility of vitiligo (P < 0.05) [Table 4]. Earlier published data on vitiligo also strengthen our finding that there is no sex predilection as such for vitiligo and both sexes are affected equally.[1],[4]

In general population, slow allele is present in up to 90% of Arab population,[18] 40%–60% in Caucasians including Indians,[21],[24],[31] 5%–25% in East Asians,[18] and 74% in south Indians.[32] In this study, frequencies of NAT2 slow alleles were observed 45% and it has been in accordance to Caucasians[31] and previous study pertaining to north Indians (44.3%).[24] Differences of distribution of slow allele of NAT2 between north Indian and south Indian population is due to the different ethnic/geographical environment.

To the best of our knowledge, this is the first study in an Indian population to explore NAT2 genotypes for the vitiligo risk. To evaluate the association study, an adequately large sample size is warranted. In current case–control study, a limited sample size was employed, which underscores the need for further large epidemiological studies to confirm our findings. Another limitation of the present study is that NAT2 has > 59 SNPs and we have examined three SNPs only. Furthermore, it has been warranted to study the other SNPs of NAT2 in large sample size too for exploring of their involvement in the risk of vitiligo.

In conclusion, this study indicates that NAT2 slow acetylator genotype exhibits significant association for the risk of vitiligo, especially in disease predisposition and initiation.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA. Epidemiology of vitiligo and associated autoimmune diseases in caucasian probands and their families. Pigment Cell Res 2003;16:208-14.  Back to cited text no. 1
    
2.
Nunes DH, Esser LM. Vitiligo: Epidemiological profile and the association with thyroid diseases. An Bras Dermatol 2011;86:241-8.  Back to cited text no. 2
    
3.
Begum R, Shajel E, Agarwal D, Vagadia K, Marfatia Y. Vitiligo: Clinical profiles in Vadodra, Gujarat. Indian J Dermatol 2006;51:100-4.  Back to cited text no. 3
  [Full text]  
4.
Wang X, Du J, Wang T, Zhou C, Shen Y, Ding Y, et al. Prevalence and clinical profile of vitiligo in China: A community based study in six cities. Acta Deramatol Venereol 2013;93:62-5.  Back to cited text no. 4
    
5.
Laddha NC, Dwivedi M, Mansuri MS, Singh M, Gani AR, Yeola AP, et al. Role of oxidative stress and autoimmunity in onset and progression of vitiligo. Exp Dermatol 2014;23:352-3.  Back to cited text no. 5
    
6.
Boissy RE, Manga P. On the etiology of contact/occupational vitiligo. Pigment Cell Res 2004;17:208-14.  Back to cited text no. 6
    
7.
Schallreuter KU. Oxidative stress in the human epidermis. G Ital Dermatol Venereol 2005;140:505-14.  Back to cited text no. 7
    
8.
Moretti S, Spallanzani A, Amato L, Hauptmann G, Gallerina I, Fabiani M, et al. New insights into the pathogenesis of vitiligo: Imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 2002;15:87-92.  Back to cited text no. 8
    
9.
Gauthier Y, Cario AM, Taieb A. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy. Pigment Cell Res 2003;16:322-32.  Back to cited text no. 9
    
10.
Zhang XJ, Chan JJ, Liu JB. The genetic concept of vitiligo. J Dermatol Sci 2005;39:137-46.  Back to cited text no. 10
    
11.
Grant DM, Goodfellow GH, Sugamori KS, Durette K. Pharmacogenetics of the human arylamine N-acetyltransferases. Pharmacology 2000;61:204-11.  Back to cited text no. 11
    
12.
Thier R, Bruning T, Roos PH, Rihs HP, Golka K, Ko Y, et al. Markers of genetic susceptibility in human environmental hygiene and toxicology: The role of selected CYP, NAT and GST genes. Int J Hyg Environ Health 2003;206:149-71.  Back to cited text no. 12
    
13.
Rastogi SC, Sosted H, Johansen JD, Menne T, Bossi R. Unconsumed precursors and couplers after formation of oxidative hair dyes. Contact Dermatitis 2006;55:95-100.  Back to cited text no. 13
    
14.
Kawakubo Y, Merk HF, Masaoudi TA, Sieben S, Blomeke B. N-Acetylation of paraphenylenediamine in human skin and keratinocytes. J Pharmacol Exp Ther 2000;292:150-5.  Back to cited text no. 14
    
15.
Evans DA. An improved and simplified method of detecting the acetylator phenotype. J Med Genet 1969;6:405-7.  Back to cited text no. 15
    
16.
Available from: http://louisville.edu/medschool/pharmacology/NAT.html. [Last updated in 2010 Sep 01-03].  Back to cited text no. 16
    
17.
Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, et al. Molecular genetics of NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000;9:29-42.  Back to cited text no. 17
    
18.
Lin HJ, Han CY, Lin BK, Hardy S. Ethnic distribution of slow acetylator mutation in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994;4:125-34.  Back to cited text no. 18
    
19.
Ladero JM. Influence of polymorphic N-acetyltransferases on non-malignant spontaneous disorders and on response to drugs. Curr Drug Metab 2008;9:532-7.  Back to cited text no. 19
    
20.
Kozhekbaeva ZM, Gra OA, Fadeev VS, Goldenkova-Pavlova IV, Korsunskaia IM, Bruskin SA, et al. Association of NAT2 polymorphism with risks to develop psoriasis and various dermatological diseases in Moscow population. Mol Biol (Mosk) 2009;43:62-76.  Back to cited text no. 20
    
21.
Santos EC, Pinto AC, Klumb EM, Macedo JM. Polymorphisms in NAT2 (N-acetyltransferase 2) gene in patients with systemic lupus erythematosus. Rev Bras Reumatol Engl Ed 2016;56:521-9.  Back to cited text no. 21
    
22.
Schnuch A, Westphal G, Mössner R, Uter W, Reich K. Genetic factors in contact allergy-review and future goals. Contact Dermatitis 2011;64:2-23.  Back to cited text no. 22
    
23.
Sambrook J, Fritsch E, Maniatis T. Molecular Cloning-A Laboratory Manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.  Back to cited text no. 23
    
24.
Srivastava DS, Mittal RD. Genetic polymorphism of the N-acetyltransferase 2 gene, and susceptibility to prostate cancer: A pilot study in North Indian population. BMC Urology 2005;5:1-6.  Back to cited text no. 24
    
25.
Vatsis KP, Weber WW, Bell DA. Nomenclature for N-acetyltransferase. Pharmacogenetics 1995;5:1-17.  Back to cited text no. 25
    
26.
Bloemeke B, Brans R, Coenraads P, Dickel H, Bruckner T, Hein DW, et al. Para-phenylenediamine and allergic sensitization: Risk modification by N-acetyltransferase 1 and 2 genotypes. Br J Dermatol 2009;161:1130-5.  Back to cited text no. 26
    
27.
Gawrońska-Szklarz B, Luszawska-Kutrzeba T, Czaja-Bulsa G, Kurzawski G. Relationship between acetylation polymorphism and risk of atopic diseases. Clin Pharmacol Ther 1999;65:562-9.  Back to cited text no. 27
    
28.
Von Schmiedeberg S, Fritsche E, Ronnau AC, Specker C, et al. Polymorphisms of the xenobiotic metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus. Adv Exp Med Biol 1999;455:147-52.  Back to cited text no. 28
    
29.
Wolkenstein P, Carriere V, Charue D, Bastuji-Garin S, Revuz J, Roujeau JC, et al. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995;5:255-8.  Back to cited text no. 29
    
30.
Nacak M, Erbagci Z, Aynacioglu AS. Human arylamine N-acetyltransferase 2 polymorphism and susceptibility to allergic contact dermatitis. Int J Dermatol 2006;45:323-6.  Back to cited text no. 30
    
31.
Xie HG, Xu ZH, Ou-Yang DS, Shu Y, Yang DL, Wang JS, et al. Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese population. Pharmacogenetics 1997;7:503-14.  Back to cited text no. 31
    
32.
Anitha A, Banerjee M. Arylamine N-acetyltransferase 2 polymorphism in the ethnic populations of South India. Int J Mol Med 2003;11:125-31.  Back to cited text no. 32
    



 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4]



 

Top
Print this article  Email this article
 
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Article in PDF (310 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
   Introduction
    Materials and Me...
   Results
   Discussion
    References
    Article Tables

 Article Access Statistics
    Viewed1058    
    Printed40    
    Emailed0    
    PDF Downloaded57    
    Comments [Add]    

Recommend this journal